

Takeda renames heartburn drug to avoid errors

March 4 2010

(AP) -- Federal regulators said Thursday that Takeda Pharmaceuticals will change the name of a heartburn drug that has repeatedly been confused by pharmacists with drugs meant to treat cancer and other ailments.

The [Food and Drug Administration](#) says the Japanese drugmaker will market its drug Kapidex under the name Dexilant, beginning next month.

Since its approval last January, the FDA says pharmacists have confused Kapidex with two other drugs: Casodex, a [prostate cancer](#) drug, and Kadian, a narcotic pain reliever.

Casodex is marketed by AstraZeneca. Kadian is marketed by Actavis Kadian LLC.

FDA says no other changes are planned for Kapidex beyond the name change.

©2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: Takeda renames heartburn drug to avoid errors (2010, March 4) retrieved 5 May 2024 from <https://medicalxpress.com/news/2010-03-takeda-renames-heartburn-drug-errors.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.